CSPC, Hengrui, and Kelun once again proved themselves, "transformation" brings glory to the top 500 list

Original title: top 500 21 pharmaceutical companies reveal secrets! Stone medicine, Hengrui and Kelun are on the list! 》On the evening of July 10, fortune Chinese released the 2019 Fortune 500 list The total operating revenue of the 500 listed companies in this year's list reached 45.5 trillion yuan, an increase of 14.8% over last year, while the annual revenue threshold of the listed companies once again increased to 16.238 billion yuan, 17% higher than last year; the top companies in the list are still Sinopec, PetroChina and CSCEC It is worth noting that among the 500 listed companies, there are 21 pharmaceutical companies on the list, among which the top three are China control, China Resources and Shanghai pharmaceutical, reflecting the "Matthew effect" brought about by the increased concentration of the pharmaceutical market; the listing of Shihua, Hengrui and Columbus on the 2019 list undoubtedly shows the market benefits brought by the innovation and transformation of the Chinese pharmaceutical industry! The main theme of transformation and upgrading of pharmaceutical enterprises in the Fortune 500 in 2019 can be seen from the analysis of pharmaceutical innovation Pharmaceutical commercial enterprises represented by guokong, Shangyao, China Resources, Jiuzhoutong, Ruikang pharmaceutical, Huadong pharmaceutical, etc have been in the forefront of the fortune list for many years On the one hand, it benefits from the huge circulation demand of China's pharmaceutical market On the other hand, in recent years, the reshuffle of pharmaceutical circulation market and channel merger and acquisition caused by the "two vote system", "business to value-added" and "three phases of golden tax" have brought the market concentration improvement, which makes these national or regional pharmaceutical industry leaders continuously integrate and upgrade the volume Compared with the ranking in 2018, it can be found that the pharmaceutical industry continued to enjoy a high popularity, and large pharmaceutical enterprises such as Guangzhou Baiyunshan Pharmaceutical Group, China biopharmaceutical, humanwell pharmaceutical, and tisley have been on the list Star enterprises of traditional Chinese medicine such as Yunnan Baiyao and Kangmei pharmaceutical also performed well, although the ranking fluctuated After entering the "post hundred billion era", Guangyao group's goal has been adjusted to strive to hit the world's top 500 by 2020 and become a world-class enterprise In order to sprint and achieve this new goal, it is obvious that it is particularly important to improve our ranking in the top 500 of China With a series of stock transformation and upgrading, promoting innovation driven development such as incremental innovation landing, Guangzhou Baiyunshan Pharmaceutical Group has increased its ranking in fortune China's top 500 by 137 In addition, the ranking of Ruikang pharmaceutical and China biopharmaceutical industry has also been greatly improved It is particularly noteworthy that the three major pharmaceutical industry innovation enterprises, namely, Shiyao, Hengrui and Kelun, are listed on the top 500 list of 2019 fortune China From 2013 to 2018, the revenue share of innovative medicine business of Shiyao group increased from 19.3% to 49.2% in the past five years, contributing nearly half of the total In the whole year of 2018, only 1 / 4 of the innovative drug business revenue increased by 57.2% to HK $10.344 billion year on year, and the growth rate was an amazing three digit, 123.3% As the "first brother" of China's pharmaceutical innovation, Hengrui attracted the industry's attention in the first half of this year with a series of innovative "achievements" According to statistics, since 2019, in the public announcement of Hengrui medicine, there have been more than 20 news about the product being approved for marketing, passing the consistency evaluation or carrying out clinical trials, most of which are about the important progress of new drugs of category 1.1 Since 2012, Kelun pharmaceutical has launched the innovation driven development strategy, with R & D investment totaling more than 4 billion yuan The company has completed the platform construction and system establishment in product innovation, and has realized the continuous listing of products, which has promoted the company to complete the transformation from simple infusion to innovation oriented comprehensive pharmaceutical enterprises Chinese biopharmaceuticals were listed in Hong Kong in 2000, initially focusing on liver disease drugs In recent years, with the company's R & D pipeline gradually expanding to multiple treatment fields, the company's product line covers all kinds of pharmaceutical R & D platforms, production and sales system industry chain Its Zhengda Tianqing has more than 16 billion products, supporting the parent company's performance of China's biopharmaceutical "half sky", known as the "king of first imitation" It is generally believed in the industry that when China leaps to become the second largest pharmaceutical market in the world, "qualitative change is needed after quantitative change" has become the consensus of many parties in the field of Chinese medicine, while innovation has become the key direction of "qualitative change" in the Chinese pharmaceutical market How to respond to regulatory policies and favorable market conditions is undoubtedly the key to winning in the new era of the pharmaceutical industry This article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.